Celmatix presents six study findings at ASRMs annual meeting Celmatix.

‘There are therefore many unanswered questions about why some ladies struggle with fertility. These questions create hard decisions for ladies and their healthcare providers. Our goal is to offer tools and resources that produce this process as informed and evidence-structured as possible.’ The oral abstracts offered by Celmatix were: Patients Discontinue Assisted Reproductive Technology PREMATURILY .: The Outcomes of a big Multiyear Cohort Study A Novel Role for Genomic Copy Quantity Variants in Female Infertility Accurate Prediction of the Number of Cycles to Achieve Live Birth The three poster presentations were: Improved Dedication of Ectopic Pregnancy Risks in Patients Undergoing In Vitro Fertilization Using Time-To-Event Models Entire Genome Sequencing for Feminine Infertility Biomarker Discovery Targeted Resequencing Sheds Light on the Etiology of Unexplained Female Infertility..The Duke experts examined research from those shown on ClinicalTrials.gov, and found that typically 13 just.4 % of eligible trials reported findings within the required one-year window. For industry-sponsored trials, the rate was 17 %. It had been 5.7 % for trials funded by academic or government sources apart from the NIH and 8.1 % for NIH-funded trials. Compliance improved over time. At five years, 41.5 % of industry-funded trials, 27.7 % of academic/non-NIH-funded trials, and 38.9 % of NIH-funded trials had reported results. The general public, along with healthcare providers, want ‘open research,’ said Eric Peterson, M.D., executive director of the Duke Clinical Research Institute and co-writer of the paper.

Other entries from category "urology":

Random entries